Compare ARK Genomic Revolution ETF (ARKG) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Union Pacific Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Union Pacific Corporation trades at $286.43 (market cap $170.37B). The key difference: Union Pacific Corporation pays a 1.92% dividend while ARK Genomic Revolution ETF pays none, and Union Pacific Corporation is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | UNP | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $286.96 |
52-Week Low | $23.09 | $214.91 |
Market Cap | — | $170.37B |
Enterprise Value | — | $200.84B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Union Pacific (UNP) trades at $286.96, up 0.67% today, with strong technical momentum indicated by bullish moving averages. The company maintains robust fundamentals with a 29.2% net income margin and consistent earnings beats in recent quarters. Key developments include the proposed $85 billion merger with Norfolk Southern, though regulatory scrutiny remains. Cash flow from operations remains healthy at $9.29 billion for 2025, supporting dividend payments and strategic initiatives.
Outlook remains positive with analyst consensus targeting $296.27, though risks include merger approval uncertainties and a class-action lawsuit. The stock's current valuation at 23.62 P/E reflects premium pricing, requiring sustained earnings growth to justify further upside. Near-term focus is on Q2 2026 earnings release scheduled for July 23, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
